Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.

Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  3. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  4. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  7. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  8. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  9. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  10. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  11. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  12. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  13. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  14. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  15. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  16. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  17. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  18. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  19. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  20. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  21. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  22. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  23. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  24. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  25. Xu K, et al. 2023. Elife. 12:. PubMed
  26. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  27. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  28. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  29. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  30. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  31. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  32. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  33. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  34. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  35. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  36. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  37. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  38. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  39. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  40. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  41. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  42. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  43. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  44. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  45. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  46. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  47. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  48. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  49. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  50. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  51. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  52. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  53. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  54. Healy LM, et al. 2020. Glia. 68:811. PubMed
  55. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  56. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  57. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  58. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  59. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  60. Miek L, et al. 2022. Immunology. 166:47. PubMed
  61. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  62. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  63. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  64. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  65. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  66. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  67. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  68. Ma T, et al. 2022. Elife. 11: . PubMed
  69. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  70. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  71. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  72. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  73. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  74. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  75. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  76. Balood M, et al. 2022. Nature. 611:405. PubMed
  77. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  78. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  79. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  80. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  81. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  82. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  83. Pleuger C, et al. 2022. Elife. 11: . PubMed
  84. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  85. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  86. Krammer S, et al. 2022. Cells. 12: . PubMed
  87. Chan L, et al. 2022. Cells. 12: . PubMed
  88. Cousin N, et al. 2022. Cells. 12: . PubMed
  89. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  90. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  91. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  92. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  93. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  94. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  95. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  96. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  97. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  98. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  99. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  100. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  101. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  102. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  103. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  104. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  105. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  106. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  107. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  108. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  109. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  110. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  111. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  112. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  113. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  114. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  115. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  116. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  117. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  118. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  119. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  120. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  121. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  122. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  123. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  124. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  125. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  126. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  127. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  128. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  129. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  130. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  131. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  132. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  133. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  134. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  135. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  136. Toomer G, et al. 2022. Viruses. 14:. PubMed
  137. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  138. Price P, et al. 2014. J Virol. 88:10840. PubMed
  139. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  140. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  141. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  142. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  143. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  144. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  145. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  146. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  147. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  148. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  149. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  150. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  151. Munoz MA, et al. 2021. Elife. 10:. PubMed
  152. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  153. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  154. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  155. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  156. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  157. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  158. Yu X, et al. 2021. Nature. 594:560. PubMed
  159. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  160. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  161. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  162. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  163. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  164. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  165. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  166. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  167. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  168. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  169. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  170. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  171. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  172. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  173. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  174. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  175. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  176. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  177. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  178. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  179. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  180. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  181. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  182. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  183. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  184. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  185. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  186. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  187. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  188. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  189. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  190. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  191. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  192. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  193. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  194. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  195. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  196. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  197. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  198. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  199. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  200. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  201. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  202. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  203. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  204. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  205. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  206. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  207. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  208. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  209. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  210. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  211. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  212. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  213. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  214. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  215. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  216. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  217. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  218. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  219. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  220. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  221. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  222. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  223. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  224. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  225. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  226. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  227. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  228. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  229. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  230. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  231. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  232. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  233. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  234. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  235. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  236. Romine KA, et al. 2021. Cancer Discov. . PubMed
  237. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  238. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  239. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  240. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  241. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  242. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  243. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  244. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  245. Köchl R, et al. 2020. Elife. 9:00. PubMed
  246. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  247. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  248. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  249. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  250. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  251. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  252. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  253. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  254. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  255. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  256. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  257. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  258. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  259. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  260. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  261. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  262. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  263. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  264. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  265. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  266. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  267. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  268. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  269. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  270. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  271. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  272. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  273. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  274. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  275. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  276. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  277. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  278. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  279. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  280. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  281. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  282. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  283. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  284. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  285. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  286. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  287. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  288. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  289. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  290. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  291. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  292. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  293. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  294. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  295. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  296. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  297. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  298. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  299. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  300. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  301. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  302. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  303. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  304. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  305. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  306. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  307. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  308. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  309. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  310. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  311. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  312. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  313. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  314. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  315. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  316. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  317. Barington L, et al. 2022. Cells. 11:. PubMed
  318. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  319. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  320. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  321. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  322. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  323. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  324. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  325. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  326. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  327. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  328. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  329. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  330. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  331. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  332. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  333. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  334. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  335. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  336. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  337. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  338. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  339. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  340. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  341. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  342. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  343. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  344. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  345. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  346. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  347. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  348. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  349. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  350. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  351. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  352. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  353. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  354. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  355. Kumar S, et al. 2022. Gut. . PubMed
  356. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  357. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  358. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  359. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  360. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  361. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  362. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  363. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  364. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  365. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  366. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  367. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  368. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  369. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  370. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  371. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  372. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  373. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  374. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  375. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  376. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  377. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  378. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  379. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  380. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  381. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  382. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  383. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  384. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  385. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  386. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  387. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  388. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  389. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  390. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  391. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  392. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  393. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  394. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  395. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  396. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  397. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  398. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  399. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  400. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  401. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  402. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  403. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  404. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  405. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  406. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  407. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  408. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  409. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  410. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  411. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  412. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  413. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  414. Yuan C, et al. 2018. iScience. 11:13. PubMed
  415. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  416. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  417. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  418. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  419. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  420. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  421. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  422. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  423. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  424. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  425. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  426. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  427. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  428. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  429. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  430. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  431. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  432. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  433. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  434. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  435. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  436. Spath S, et al. 2022. iScience. 25:104998. PubMed
  437. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  438. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  439. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  440. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  441. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  442. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  443. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  444. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  445. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  446. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  447. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  448. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  449. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  450. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  451. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  452. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  453. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  454. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  455. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  456. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  457. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  458. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  459. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  460. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  461. Li J, et al. 2015. Cancer Res. 75:508. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 8    Revision Date: 01/27/2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account